Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GALK1 | P51570 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4206179 | 1.00 | MAPT (0.50) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL458177 | 0.77 | APP (0.78) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL9170804 | 0.77 | APP (0.78) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL9170800 | 0.77 | APP (0.78) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL458178 | 0.77 | APP (0.78) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL14947048 | 0.77 | APP (0.78) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL6047849 | 0.74 | NPC1 (0.42) | RAB9ANPC1CYP19A1MEN1KMT2A | |
| SCHEMBL9647725 | 0.73 | KDM1A (0.34) | — | |
| SCHEMBL9647720 | 0.73 | KDM1A (0.34) | — | |
| SCHEMBL11375977 | 0.72 | APP (0.69) | MAPTRAB9ANPC1APPFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844157-A2 | STRATEGIES FOR DESIGNING DRUGS THAT TARGET THE SIR2 FAMILY OF ENZYMES | The Johns Hopkins University (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2006081329-A2 | STRATEGIES FOR DESIGNING DRUGS THAT TARGET THE SIR2 FAMILY OF ENZYMES | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-08-03 | — | — | WO | claimed |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | BIOMOL INTERNATIONAL, INC. | 2006-01-19 | — | — | US | claimed |
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-10-27 | — | — | US | disclosed |
| EP-2670404-B1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | UNIV PRINCETON (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20160296523-A1 | Sirtuin Modulators as Inhibitors of Cytomegalovirus | THE TRUSTEES OF PRINCETON UNIVERSITY | 2016-10-13 | — | — | US | disclosed |
| US-20130338178-A1 | SIRTUIN MODULATORS AS INHIBITORS OF CYTOMEGALOVIRUS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2670404-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | The Trustees of Princeton University (US) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012106509-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20090012130-A1 | Strategies for Designing Drugs that Target the Sir2 Family of Enzymes | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1844157-A2 | STRATEGIES FOR DESIGNING DRUGS THAT TARGET THE SIR2 FAMILY OF ENZYMES | The Johns Hopkins University (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006081329-A2 | STRATEGIES FOR DESIGNING DRUGS THAT TARGET THE SIR2 FAMILY OF ENZYMES | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | BIOMOL INTERNATIONAL, INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | SIRT1, SIRT2, SIRT7 | MAPT 2621/4885RAB9A 3558/4885NPC1 2730/4885 |
| US-20160296523-A1 | Sirtuin Modulators as Inhibitors of Cytomegalovirus | SIRT1, SIRT2, SIRT7 | MAPT 2621/4885RAB9A 3558/4885NPC1 2730/4885 |
| US-20130338178-A1 | SIRTUIN MODULATORS AS INHIBITORS OF CYTOMEGALOVIRUS | SIRT1, SIRT2, SIRT7 | MAPT 2621/4885RAB9A 3558/4885NPC1 2730/4885 |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | SIRT1, SIRT7, SIRT5 | MAPT 3039/4885RAB9A 3172/4885NPC1 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.